219 related articles for article (PubMed ID: 7386598)
21. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
22. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.
Nilsson C; Forsman J; Hassan Z; Abedi-Valugerdi M; O'Connor C; Concha H; Jansson M; Hassan M
Exp Hematol; 2005 Mar; 33(3):380-7. PubMed ID: 15730862
[TBL] [Abstract][Full Text] [Related]
23. Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity.
Leonard JP; Neben TY; Kozitza MK; Quinto CM; Goldman SJ
Exp Hematol; 1996 Feb; 24(2):270-6. PubMed ID: 8641352
[TBL] [Abstract][Full Text] [Related]
24. Monocyte chemoattractant protein-1 stimulates tumor necrosis and recruitment of macrophages into tumors in tumor-bearing nude mice: increased granulocyte and macrophage progenitors in murine bone marrow.
Hoshino Y; Hatake K; Kasahara T; Takahashi Y; Ikeda M; Tomizuka H; Ohtsuki T; Uwai M; Mukaida N; Matsushima K
Exp Hematol; 1995 Aug; 23(9):1035-9. PubMed ID: 7635182
[TBL] [Abstract][Full Text] [Related]
25. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
26. Effect of taurine on leucocyte function.
Wang L; Zhao N; Zhang F; Yue W; Liang M
Eur J Pharmacol; 2009 Aug; 616(1-3):275-80. PubMed ID: 19490912
[TBL] [Abstract][Full Text] [Related]
27. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
Fisher B; Gebhardt M
Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
[TBL] [Abstract][Full Text] [Related]
28. NTP Toxicology and Carcinogenesis Studies of Phenolphthalein (CAS No. 77-09-8) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Nov; 465():1-354. PubMed ID: 12579199
[TBL] [Abstract][Full Text] [Related]
29. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.
McIntosh JK; Mulé JJ; Travis WD; Rosenberg SA
Cancer Res; 1990 Apr; 50(8):2463-9. PubMed ID: 2317830
[TBL] [Abstract][Full Text] [Related]
30. Effect of X-rays and cyclophosphamide on solid tumors and naturally occurring metastases in mice.
Chu AM; Fowler JF
Cancer Res; 1982 May; 42(5):1943-9. PubMed ID: 7066905
[TBL] [Abstract][Full Text] [Related]
31. Effects of tumor bearing on the dynamics of host hemopoietic cells.
Lala PK
Cancer Treat Rep; 1976 Dec; 60(12):1781-9. PubMed ID: 1026335
[TBL] [Abstract][Full Text] [Related]
32. Detection of residual murine LPC-1 myeloma cells from bone marrow cell mixture after purging by 4-hydroperoxycyclophosphamide.
Frondoza CG; Sinha S; Trivedi SM; Humphrey RL; Colvin OM
Exp Hematol; 1987 Jul; 15(6):715-8. PubMed ID: 3297761
[TBL] [Abstract][Full Text] [Related]
33. Combined interleukin-1 beta/interleukin-6 treatment in mice: synergistic myelostimulatory activity and myelorestorative effect after cyclophosphamide-induced myelosuppression.
Tritarelli E; Greco G; Testa U; Belardelli F; Peschle C; Proietti E
Cancer Res; 1994 Dec; 54(24):6469-76. PubMed ID: 7987845
[TBL] [Abstract][Full Text] [Related]
34. Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas.
Yu S; Lannin DR; Tsui-Collins AL; McKhann CF
Cancer Res; 1980 Aug; 40(8 Pt 1):2756-61. PubMed ID: 7388826
[TBL] [Abstract][Full Text] [Related]
35. A novel anti-inflammatory function of human galectin-1: inhibition of hematopoietic progenitor cell mobilization.
Kiss J; Kunstár A; Fajka-Boja R; Dudics V; Tóvári J; Légrádi A; Monostori E; Uher F
Exp Hematol; 2007 Feb; 35(2):305-13. PubMed ID: 17258079
[TBL] [Abstract][Full Text] [Related]
36. Cyclophosphamide-induced tumour regression of cyclophosphamide-resistant L5178Y lymphoma through suppressor cells elimination.
Andrade-Mena CE
Int J Tissue React; 1994; 16(2):95-103. PubMed ID: 7960506
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte-colony stimulating factor impedes recovery from damage caused by cytotoxic agents through increased differentiation at the expense of self-renewal.
van Os R; Robinson S; Sheridan T; Mauch PM
Stem Cells; 2000; 18(2):120-7. PubMed ID: 10742384
[TBL] [Abstract][Full Text] [Related]
38. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
[TBL] [Abstract][Full Text] [Related]
39. Immuno-enhancement effects of Shenqi Fuzheng Injection on cyclophosphamide-induced immunosuppression in Balb/c mice.
Wang J; Tong X; Li P; Cao H; Su W
J Ethnopharmacol; 2012 Feb; 139(3):788-95. PubMed ID: 22212503
[TBL] [Abstract][Full Text] [Related]
40. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
